Search

Your search keyword '"van der Poel, Henk G."' showing total 1,498 results
Start Over Author "van der Poel, Henk G."
1,498 results on '"van der Poel, Henk G."'

2. Delphi consensus project on prostate-specific membrane antigen (PSMA)–targeted surgery—outcomes from an international multidisciplinary panel

Author

Berrens, Anne-Claire, Scheltema, Matthijs, Maurer, Tobias, Hermann, Ken, Hamdy, Freddie C., Knipper, Sophie, Dell’Oglio, Paolo, Mazzone, Elio, de Barros, Hilda A., Sorger, Jonathan M., van Oosterom, Matthias N., Stricker, Philip D., van Leeuwen, Pim J., Rietbergen, Daphne D. D., Valdes Olmos, Renato A., Vidal-Sicart, Sergi, Carroll, Peter R., Buckle, Tessa, van der Poel, Henk G., and van Leeuwen, Fijs W. B.

Published
2024
Full Text
View/download PDF

8. Middellangetermijnoverleving na open versus robotgeassisteerde radicale cystectomie in Nederland: resultaten van de ‘SNAPSHOT’ cystectomie

Author

van Ginkel, Noor, Vis, André N., Boormans, Joost L., van der Poel, Henk G., van der Schoot, Deric K. E., Aben, Katja K. H., Hermans, Tom J. N., Meijer, Dennie, Voortman, Jens, Arends, Tom J. H., Ausems, Peter J., Baselmans, Dorine, Berger, Christian P. A. M., Berrens, Anne-Claire, Bickerstaffe, Henry, Bos, Siebe D., Braam, Marlene, Buddingh, K. Tim, Claus, Sebastiaan, Dekker, Karen, van Doeveren, Thomas, Einerhand, Sarah M. H., Fossion, Laurent M. C. Laurent, Hinsenveld, Florentien J., van Gennep, Erik J., Grondhuis Palacios, Lorena A., Hobijn, Mandy M., van Huystee, Suzanne H., Jaspers-Valentijn, Martinique, Klaver, O. Sjoerd, Koldewijn, Evert L., Korsten, Linn, Lenting, Anne, Lentjes, Koen J., Luiting, Henk B., van der Meer, Saskia, Mertens, Laura, Nieuwenhuijzen, Jakko A., Noordzij, M. Arjen, Nooter, Ronald I., Notenboom, Marije, Oomen, Robert J. A., van Roermund, Joep G. H., de Rooij, Judith, Roshani, Hossain, Schrier, Bart P., van der Slot, Michelle A., Somford, D. M. Rik, Stelwagen, Piter-Jan, Stroux, Aukje M. A., van der West, Alwine, Wijsman, Bart P., Windt, Willemijn A. K. M., van Zanten, Paul, and van Beek, Sytse C.

Published
2023
Full Text
View/download PDF

15. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Author

Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2024
Full Text
View/download PDF

16. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature

Author

Sood, Akshay, Kishan, Amar U., Evans, Christopher P., Feng, Felix Y., Morgan, Todd M., Murphy, Declan G., Padhani, Anwar R., Pinto, Peter, Van der Poel, Henk G., Tilki, Derya, Briganti, Alberto, and Abdollah, Firas

Published
2024
Full Text
View/download PDF

18. 3D-Reconstructed Contact Surface Area and Tumour Volume on Magnetic Resonance Imaging Improve the Prediction of Extraprostatic Extension of Prostate Cancer

Author

Veerman, Hans, Hoeks, Caroline M. A., Sluijter, Judith H., van der Eijk, Jari A., Boellaard, Thierry N., Roeleveld, Ton A., van der Sluis, Tim M., Nieuwenhuijzen, Jakko A., Wit, Esther, Rijkhorst, Erik-Jan, Heymans, Martijn W., van Alphen, Maarten J. A., van Veen, Robert L. P., Vis, André N., van der Poel, Henk G., and van Leeuwen, Pim J.

Published
2023
Full Text
View/download PDF

20. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography

Author

Vis, André N., Meijer, Dennie, Roberts, Matthew J., Siriwardana, Amila R., Morton, Andrew, Yaxley, John W., Samaratunga, Hemamali, Emmett, Louise, van de Ven, Peter M., Heymans, Martijn W., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., Stricker, Phillip, Haynes, Anne-Maree, Oprea-Lager, Daniela E., Coughlin, Geoffrey D., and van Leeuwen, Pim J.

Published
2023
Full Text
View/download PDF

22. Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective

Author

Vreeburg, Manon T. A., Azargoshasb, Samaneh, van Willigen, Danny, Molenaar, Tom, van Oosterom, Matthias N., Buckle, Tessa, Slof, Leon J., Klop, Martin, Karakullukcu, Baris, Donswijk, Maarten, van der Poel, Henk G., van Leeuwen, Fijs W. B., Brouwer, Oscar R., and Rietbergen, Daphne D. D.

Published
2023
Full Text
View/download PDF

29. Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Author

Pomerantz, Mark M, Qiu, Xintao, Zhu, Yanyun, Takeda, David Y, Pan, Wenting, Baca, Sylvan C, Gusev, Alexander, Korthauer, Keegan D, Severson, Tesa M, Ha, Gavin, Viswanathan, Srinivas R, Seo, Ji-Heui, Nguyen, Holly M, Zhang, Baohui, Pasaniuc, Bogdan, Giambartolomei, Claudia, Alaiwi, Sarah A, Bell, Connor A, O’Connor, Edward P, Chabot, Matthew S, Stillman, David R, Lis, Rosina, Font-Tello, Alba, Li, Lewyn, Cejas, Paloma, Bergman, Andries M, Sanders, Joyce, van der Poel, Henk G, Gayther, Simon A, Lawrenson, Kate, Fonseca, Marcos AS, Reddy, Jessica, Corona, Rosario I, Martovetsky, Gleb, Egan, Brian, Choueiri, Toni, Ellis, Leigh, Garraway, Isla P, Lee, Gwo-Shu Mary, Corey, Eva, Long, Henry W, Zwart, Wilbert, and Freedman, Matthew L

Subjects
Agricultural, Veterinary and Food Sciences, Biological Sciences, Bioinformatics and Computational Biology, Genetics, Agricultural Biotechnology, Aging, Human Genome, Urologic Diseases, Cancer, Prostate Cancer, 2.1 Biological and endogenous factors, Aetiology, Cell Line, Cell Line, Tumor, Disease Progression, Epigenomics, Gene Expression Regulation, Neoplastic, HEK293 Cells, Hepatocyte Nuclear Factor 3-alpha, Humans, Male, Prostate, Prostatic Neoplasms, Receptors, Androgen, Regulatory Sequences, Nucleic Acid, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription factor. We generated 268 epigenomic datasets spanning two state transitions-from normal prostate epithelium to localized PCa to metastases-in specimens derived from human tissue. We discovered that reprogrammed AR sites in metastatic PCa are not created de novo; rather, they are prepopulated by the transcription factors FOXA1 and HOXB13 in normal prostate epithelium. Reprogrammed regulatory elements commissioned in metastatic disease hijack latent developmental programs, accessing sites that are implicated in prostate organogenesis. Analysis of reactivated regulatory elements enabled the identification and functional validation of previously unknown metastasis-specific enhancers at HOXB13, FOXA1 and NKX3-1. Finally, we observed that prostate lineage-specific regulatory elements were strongly associated with PCa risk heritability and somatic mutation density. Examining prostate biology through an epigenomic lens is fundamental for understanding the mechanisms underlying tumor progression.

Published
2020

39. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men

Author

Wagensveld, Ivo M., Osses, Daniel F., Groenendijk, Pieter M., Zijta, Frank M., Busstra, Martijn B., Rociu, Elena, Barentsz, Jelle O., Michiel Sedelaar, J.P., Arbeel, Berber, Roeleveld, Ton, Geenen, Remy, Koeter, Ingrid, van der Meer, Saskia A., Cappendijk, Vincent, Somford, Rik, Klaver, Sjoerd, Van der Lely, Hans, Wolters, Tineke, Hellings, Willem, Leter, Maicle R., Van der Poel, Henk G., Heijmink, Stijn W.T.P.J., Debruyne, Frans, Immerzeel, Jos, Leijte, Joost, van Roermund, Joep, Miclea, Razvan, Planken, Erik, Vis, André N., Jan de Jong, Igle, Tijsterman, Jasper, Wolterbeek, Derk, Claessen, Anoesjka, Vrijhof, Eric, Nederend, Joost, Van Leenders, Geert J.L.H., Bangma, Chris H., Krestin, Gabriel P., Remmers, Sebastiaan, and Schoots, Ivo G.

Published
2022
Full Text
View/download PDF

46. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer

Author

Meijer, Dennie, Eppinga, Wietse S.C., Mohede, Roos M., Vanneste, Ben G.L., Meijnen, Philip, Meijer, Otto W.M., Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Ettema, Rosemarijn H., Oudshoorn, Frederik H.K., van Leeuwen, Pim J., van der Poel, Henk G., Donswijk, Maarten L., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2022
Full Text
View/download PDF

47. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy

Author

Willemse, Peter-Paul M., Davis, Niall F., Grivas, Nikolaos, Zattoni, Fabio, Lardas, Michael, Briers, Erik, Cumberbatch, Marcus G., De Santis, Maria, Dell'Oglio, Paolo, Donaldson, James F., Fossati, Nicola, Gandaglia, Giorgio, Gillessen, Silke, Grummet, Jeremy P., Henry, Ann M., Liew, Matthew, MacLennan, Steven, Mason, Malcolm D., Moris, Lisa, Plass, Karin, O'Hanlon, Shane, Omar, Muhammad Imran, Oprea-Lager, Daniela E., Pang, Karl H., Paterson, Catherine C., Ploussard, Guillaume, Rouvière, Olivier, Schoots, Ivo G., Tilki, Derya, van den Bergh, Roderick C.N., Van den Broeck, Thomas, van der Kwast, Theodorus H., van der Poel, Henk G., Wiegel, Thomas, Yuan, Cathy Yuhong, Cornford, Philip, Mottet, Nicolas, and Lam, Thomas B.L.

Published
2022
Full Text
View/download PDF

48. Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.

Author

Roberts, Matthew J., Papa, Nathan, Veerman, Hans, de Bie, Katelijne, Morton, Andrew, Franklin, Anthony, Raveenthiran, Sheliyan, Yaxley, William J., Donswijk, Maarten L., van der Poel, Henk G., Samaratunga, Hemamali, Wong, David, Brown, Nicholas, Parkinson, Robert, Gianduzzo, Troy, Kua, Boon, Coughlin, Geoffrey D., Oprea‐Lager, Daniela E., Emmett, Louise, and van Leeuwen, Pim J.

Abstract

Objectives: To construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. Patients and Methods: Patients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence‐free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre‐ and post‐surgical parameters and primary tumour maximum standardised uptake value (SUVmax) on diagnostic PSMA‐PET/CT. Calibration was assessed in an external dataset from the Netherlands with the same inclusion criteria. Results: Data from 846 patients were used to develop the models. Tumour SUVmax was associated with worse predicted 3‐year BRFS for both pre‐ and post‐surgical models. SUVmax change from 4 to 16 lessened the predicted 3‐year BRFS from 66% to 42% for a patient aged 65 years with typical pre‐surgical parameters (PSA level 8 ng/mL, Prostate Imaging‐Reporting and Data System score 4/5 and biopsy Gleason score ≥4 + 5). Considering post‐surgical variables, a patient with the same age and PSA level but pathological stage pT3a, RP Gleason score ≥4 + 5 and negative margins, SUVmax change from 4 to 16 lessened the predicted 3‐year BRFS from 76% to 61%. Calibration on an external sample (n = 464) showed reasonable performance; however, a tendency to overestimate survival in patients with good prognostic factors was observed. Conclusion: Tumour SUVmax on diagnostic PSMA‐PET/CT has utility additional to commonly recognised variables for prediction of BRFS after RP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden.

Author

Özman, Oktay, Veerman, Hans, Contieri, Roberto, Droghetti, Matteo, Donswijk, Maarten L., Hagens, Marinus J., Van Leeuwen, Pim J., Vis, André N., and van der Poel, Henk G.

Subjects
POSITRON emission tomography computed tomography, PROSTATE-specific membrane antigen, POSITRON emission tomography, COMPUTED tomography, RADICAL prostatectomy
Abstract

Objectives: To explore the factors affecting the lymph node metastasis (LNM) detection performance of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and to evaluate its prognostic value for biochemical recurrence after radical prostatectomy (RP). Methods: Patients who had intermediate- or high-risk prostate cancer and underwent robot-assisted (RA)RP between 2017 and 2021 were included. Initial lymph node staging was carried out using PSMA PET/CT. Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values were calculated. A cut-off value for LNM tumor deposit size that maximizes specificity was investigated and a post hoc specificity analysis was carried out. In survival analysis for biochemical progression-free survival (bPFS) after RP, Kaplan–Meier curves of molecular imaging (mi)N0 and miN1 patients were compared using the log-rank test and separate Cox regression models were developed to reveal the significance of PSMA PET/CT staging in pre- and post-surgery settings. Results: In 583 patients with a prevalence of pathology-proven LNM of 27.4%, overall sensitivity, specificity, PPV, and NPV of PSMA PET/CT per patient were 26.3% [95%CI 18.9–35.5], 93.9% [95%CI 84.9–100], 61.8% [95%CI 44.5–83.5], and 77.1% [95%CI 69.7–85.1], respectively. PSMA PET/CT showed a better sensitivity as LNM tumor deposit size increased (p = 0.003 OR 2.4 [95%CI 1.3–4.4]) and a better specificity in pT3-4 tumors (96.1%) versus pT2 (91.1%, p = 0.024 OR 2.7 [95%CI 1.1–6.3]). After adjustment according to 5.5 mm LNM tumor deposit size, which showed the best discriminative performance (AUC: 0.905 [95%CI 0.804–1.000, p < 0.001]), overall sensitivity tripled (90.2%, p < 0.001). The 1-year bPFS was 56.0% and 83.3% for miN1 and miN0 patients, respectively (p < 0.001). Whereas miN0pN1 was not, miN1pN1 disease was independently associated with decreased bPFS (HR:2.1 95%CI 1.3–3.4, p < 0.001). Conclusions: PSMA PET/CT has a lymph node tumor burden-dependent and cohort-driven diagnostic ability but consequently a strong independent prognostic value for predicting biochemical recurrence after RARP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results